{
  "entities": [
    {
      "id": 1,
      "text": "major depressive disorder",
      "type": "medical_condition",
      "code_system": "ICD-10",
      "code": "F33.1"
    },
    {
      "id": 2,
      "text": "selective serotonin reuptake inhibitors",
      "type": "medication",
      "code_system": "RXNORM",
      "code": "104964"
    },
    {
      "id": 3,
      "text": "electroconvulsive therapy",
      "type": "treatment_type",
      "code_system": "CPT",
      "code": "90870"
    },
    {
      "id": 4,
      "text": "remission",
      "type": "outcome",
      "code_system": null,
      "code": null
    },
    {
      "id": 5,
      "text": "depression-focused psychotherapy",
      "type": "treatment_type",
      "code_system": null,
      "code": null
    },
    {
      "id": 6,
      "text": "combination of medications and psychotherapy",
      "type": "treatment_type",
      "code_system": null,
      "code": null
    },
    {
      "id": 7,
      "text": "monoamine oxidase inhibitors",
      "type": "medication",
      "code_system": "RXNORM",
      "code": "31350"
    },
    {
      "id": 8,
      "text": "tricyclic antidepressants",
      "type": "medication",
      "code_system": "RXNORM",
      "code": "31356"
    },
    {
      "id": 9,
      "text": "norepinephrine reuptake inhibitors",
      "type": "medication",
      "code_system": "RXNORM",
      "code": "31355"
    },
    {
      "id": 10,
      "text": "cognitive behavioral therapy",
      "type": "treatment_type",
      "code_system": null,
      "code": null
    },
    {
      "id": 11,
      "text": "response rate",
      "type": "outcome",
      "code_system": null,
      "code": null
    },
    {
      "id": 12,
      "text": "Hamilton Depression Rating Scale",
      "type": "measure",
      "code_system": "LOINC",
      "code": "35000"
    },
    {
      "id": 13,
      "text": "treatment-resistant depression",
      "type": "medical_condition",
      "code_system": "ICD-10",
      "code": "F33.2"
    },
    {
      "id": 14,
      "text": "ketamine",
      "type": "medication",
      "code_system": "RXNORM",
      "code": "85968"
    },
    {
      "id": 15,
      "text": "esketamine",
      "type": "medication",
      "code_system": "RXNORM",
      "code": "1012028"
    },
    {
      "id": 16,
      "text": "Cognitive-behavioral therapy",
      "type": "treatment_type",
      "code_system": "CPT",
      "code": null
    },
    {
      "id": 17,
      "text": "interpersonal therapy",
      "type": "treatment_type",
      "code_system": "CPT",
      "code": null
    },
    {
      "id": 18,
      "text": "supportive therapy",
      "type": "treatment_type",
      "code_system": "CPT",
      "code": null
    },
    {
      "id": 19,
      "text": "psychoeducational intervention",
      "type": "treatment_type",
      "code_system": "CPT",
      "code": null
    },
    {
      "id": 20,
      "text": "mindfulness-based cognitive therapy",
      "type": "treatment_type",
      "code_system": "CPT",
      "code": null
    },
    {
      "id": 21,
      "text": "Cognitive Behavioral Analysis System of Psychotherapy",
      "type": "treatment_type",
      "code_system": "CPT",
      "code": null
    },
    {
      "id": 22,
      "text": "problem-solving therapy",
      "type": "treatment_type",
      "code_system": "CPT",
      "code": null
    },
    {
      "id": 23,
      "text": "marital and family therapy",
      "type": "treatment_type",
      "code_system": "CPT",
      "code": null
    },
    {
      "id": 24,
      "text": "symptom reduction",
      "type": "outcome",
      "code_system": null,
      "code": null
    },
    {
      "id": 25,
      "text": "group therapy",
      "type": "treatment_type",
      "code_system": "CPT",
      "code": null
    },
    {
      "id": 26,
      "text": "repetitive transcranial magnetic stimulation",
      "type": "treatment_type",
      "code_system": null,
      "code": null
    },
    {
      "id": 27,
      "text": "transcranial direct current stimulation",
      "type": "treatment_type",
      "code_system": null,
      "code": null
    },
    {
      "id": 28,
      "text": "vagus nerve stimulation",
      "type": "treatment_type",
      "code_system": null,
      "code": null
    },
    {
      "id": 29,
      "text": "deep brain stimulation",
      "type": "treatment_type",
      "code_system": null,
      "code": null
    },
    {
      "id": 30,
      "text": "magnetic seizure therapy",
      "type": "treatment_type",
      "code_system": null,
      "code": null
    },
    {
      "id": 31,
      "text": "patients with common comorbid conditions",
      "type": "patient_group",
      "code_system": null,
      "code": null
    },
    {
      "id": 32,
      "text": "patients at high risk of relapse",
      "type": "patient_group",
      "code_system": null,
      "code": null
    },
    {
      "id": 33,
      "text": "patients with severe and psychotic depression",
      "type": "patient_group",
      "code_system": null,
      "code": null
    },
    {
      "id": 34,
      "text": "patients with bipolar depression",
      "type": "patient_group",
      "code_system": null,
      "code": null
    },
    {
      "id": 35,
      "text": "resistant depression",
      "type": "medical_condition",
      "code_system": "ICD-10",
      "code": "F33.2"
    },
    {
      "id": 36,
      "text": "phototherapy",
      "type": "treatment_type",
      "code_system": "CPT",
      "code": null
    },
    {
      "id": 37,
      "text": "tranylcypromine",
      "type": "medication",
      "code_system": "RXNORM",
      "code": "3111"
    },
    {
      "id": 38,
      "text": "nortriptyline",
      "type": "medication",
      "code_system": "RXNORM",
      "code": "3132"
    },
    {
      "id": 39,
      "text": "phenelzine",
      "type": "medication",
      "code_system": "RXNORM",
      "code": "3134"
    },
    {
      "id": 40,
      "text": "adolescents with MDD",
      "type": "patient_group",
      "code_system": null,
      "code": null
    },
    {
      "id": 41,
      "text": "randomized controlled trial",
      "type": "study",
      "code_system": null,
      "code": null
    },
    {
      "id": 42,
      "text": "venlafaxine",
      "type": "medication",
      "code_system": "RXNORM",
      "code": "3121"
    },
    {
      "id": 43,
      "text": "bupropion",
      "type": "medication",
      "code_system": "RXNORM",
      "code": "3100"
    },
    {
      "id": 44,
      "text": "citalopram",
      "type": "medication",
      "code_system": "RXNORM",
      "code": "3095"
    },
    {
      "id": 45,
      "text": "trazodone",
      "type": "medication",
      "code_system": "RXNORM",
      "code": "3134"
    },
    {
      "id": 46,
      "text": "vortioxetine",
      "type": "medication",
      "code_system": "RXNORM",
      "code": "101156"
    },
    {
      "id": 47,
      "text": "anxious depression",
      "type": "medical_condition",
      "code_system": "ICD-10",
      "code": null
    },
    {
      "id": 48,
      "text": "treatment efficacy",
      "type": "outcome",
      "code_system": null,
      "code": null
    },
    {
      "id": 49,
      "text": "treatment-resistant depression",
      "type": "patient_group",
      "code_system": null,
      "code": null
    },
    {
      "id": 50,
      "text": "randomized, double-blind, placebo-controlled trial",
      "type": "study",
      "code_system": null,
      "code": null
    },
    {
      "id": 51,
      "text": "generalized anxiety disorder",
      "type": "medical_condition",
      "code_system": "ICD-10",
      "code": "F41.1"
    },
    {
      "id": 52,
      "text": "interpersonal psychotherapy",
      "type": "treatment_type",
      "code_system": "CPT",
      "code": null
    },
    {
      "id": 53,
      "text": "exercise",
      "type": "treatment_type",
      "code_system": null,
      "code": null
    },
    {
      "id": 54,
      "text": "major depression",
      "type": "medical_condition",
      "code_system": "ICD-10",
      "code": "F33.1"
    },
    {
      "id": 55,
      "text": "Meta-analysis of the Efficacy and Safety of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression",
      "type": "study",
      "code_system": null,
      "code": null
    },
    {
      "id": 56,
      "text": "sertraline",
      "type": "medication",
      "code_system": "RXNORM",
      "code": "672"
    },
    {
      "id": 57,
      "text": "buspirone",
      "type": "medication",
      "code_system": "RXNORM",
      "code": "3133"
    },
    {
      "id": 58,
      "text": "response",
      "type": "outcome",
      "code_system": null,
      "code": null
    },
    {
      "id": 59,
      "text": "STAR*D",
      "type": "study",
      "code_system": null,
      "code": null
    },
    {
      "id": 60,
      "text": "Quick Inventory of Depressive Symptomatology",
      "type": "measure",
      "code_system": "LOINC",
      "code": "35001-6"
    },
    {
      "id": 61,
      "text": "treatment-resistant patients",
      "type": "patient_group",
      "code_system": null,
      "code": null
    },
    {
      "id": 62,
      "text": "Quick Inventory of Depressive Symptomatology–Self-Report",
      "type": "measure",
      "code_system": "LOINC",
      "code": "35001-6"
    },
    {
      "id": 63,
      "text": "benzodiazepine",
      "type": "medication",
      "code_system": "RXNORM",
      "code": null
    },
    {
      "id": 64,
      "text": "adults with major depression",
      "type": "patient_group",
      "code_system": null,
      "code": null
    },
    {
      "id": 65,
      "text": "antidepressant therapy",
      "type": "treatment_type",
      "code_system": "CPT",
      "code": null
    },
    {
      "id": 66,
      "text": "anxious major depressive disorder",
      "type": "medical_condition",
      "code_system": "ICD-10",
      "code": "F33.1"
    },
    {
      "id": 67,
      "text": "major depressive subtypes",
      "type": "medical_condition",
      "code_system": "ICD-10",
      "code": "F33.x"
    },
    {
      "id": 68,
      "text": "fluoxetine",
      "type": "medication",
      "code_system": "RXNORM",
      "code": "5450"
    },
    {
      "id": 69,
      "text": "imipramine",
      "type": "medication",
      "code_system": "RXNORM",
      "code": "6823"
    },
    {
      "id": 70,
      "text": "antidepressant treatment",
      "type": "treatment_type",
      "code_system": "CPT",
      "code": null
    },
    {
      "id": 71,
      "text": "response to treatment",
      "type": "outcome",
      "code_system": null,
      "code": null
    }
  ],
  "relationships": [
    {
      "head": 2,
      "tail": 1,
      "type": "treats",
      "evidence": "pharmacotherapy, especially selective serotonin reuptake inhibitors antidepressants, remains the most frequent option for treating depression during the acute phase."
    },
    {
      "head": 3,
      "tail": 1,
      "type": "treats",
      "evidence": "electroconvulsive therapy is the most effective somatic therapy for depression in some specific situations."
    },
    {
      "head": 5,
      "tail": 1,
      "type": "treats",
      "evidence": "depression-focused psychotherapy is the second most common option for helping patients overcome the acute phase, maintain remission, and prevent relapses."
    },
    {
      "head": 6,
      "tail": 1,
      "type": "treats",
      "evidence": "combining medications, psychotherapy, and somatic therapies remains the most effective way to manage resistant forms of depression."
    },
    {
      "head": 1,
      "tail": 4,
      "type": "has_outcome",
      "evidence": "treatment during the acute phase of a major depressive episode aims to help the patient reach a remission state."
    },
    {
      "head": 7,
      "tail": 1,
      "type": "treats",
      "evidence": "maois have demonstrated specific efficacy in treating depression with atypical features."
    },
    {
      "head": 8,
      "tail": 1,
      "type": "treats",
      "evidence": "tcas are about as effective as other classes of antidepressants in treating major depression."
    },
    {
      "head": 2,
      "tail": 1,
      "type": "treats",
      "evidence": "ssris have demonstrated comparable efficacy to tcas in treating major depression."
    },
    {
      "head": 9,
      "tail": 1,
      "type": "treats",
      "evidence": "snris are generally considered effective as ssris in treating major depression."
    },
    {
      "head": 1,
      "tail": 4,
      "type": "has_outcome",
      "evidence": "ssris are recommended as the first-line treatment for patients with major depression."
    },
    {
      "head": 1,
      "tail": 11,
      "type": "has_outcome",
      "evidence": "in individual studies, venlafaxine and duloxetine are generally considered effective as ssris."
    },
    {
      "head": 4,
      "tail": 12,
      "type": "measured_by",
      "evidence": "the hamilton depression is commonly used to measure remission in depression."
    },
    {
      "head": 14,
      "tail": 13,
      "type": "treats",
      "evidence": "ketamine has very effects on resistant unipolar depression."
    },
    {
      "head": 15,
      "tail": 13,
      "type": "treats",
      "evidence": "esketamine was approved by the united states food and drug administration in march 2019 for treatment-resistant depression."
    },
    {
      "head": 14,
      "tail": 4,
      "type": "has_outcome",
      "evidence": "the antidepressant effect of ketamine can persist for several days but eventually wanes."
    },
    {
      "head": 15,
      "tail": 4,
      "type": "has_outcome",
      "evidence": "esketamine use must be carefully monitored due to potential risks, but it is used for treatment-resistant depression."
    },
    {
      "head": 4,
      "tail": 12,
      "type": "measured_by",
      "evidence": "the hamilton depression is commonly used to assess outcomes in depression treatment."
    },
    {
      "head": 16,
      "tail": 1,
      "type": "treats",
      "evidence": "cbt is a well-known effective treatment method for mdd."
    },
    {
      "head": 17,
      "tail": 1,
      "type": "treats",
      "evidence": "ipt is a first-line treatment for mild to moderate major depressive episodes in adults."
    },
    {
      "head": 18,
      "tail": 1,
      "type": "treats",
      "evidence": "supportive therapy is commonly used to support depressed patients."
    },
    {
      "head": 19,
      "tail": 1,
      "type": "treats",
      "evidence": "psychoeducational intervention has been recommended for patients with depression."
    },
    {
      "head": 20,
      "tail": 1,
      "type": "treats",
      "evidence": "mindfulness-based cognitive therapy is proposed to maintain and prevent depression."
    },
    {
      "head": 21,
      "tail": 1,
      "type": "treats",
      "evidence": "the european psychiatric association recommends using the cognitive behavioral analysis system of psychotherapy for treating chronic depression."
    },
    {
      "head": 22,
      "tail": 1,
      "type": "treats",
      "evidence": "problem-solving therapy has been used in different clinical situations, like preventing depression among the elderly."
    },
    {
      "head": 23,
      "tail": 1,
      "type": "treats",
      "evidence": "marital and family therapy is effective in treating some aspects of depression."
    },
    {
      "head": 16,
      "tail": 4,
      "type": "has_outcome",
      "evidence": "cbt is a well-known effective treatment method for mdd."
    },
    {
      "head": 17,
      "tail": 4,
      "type": "has_outcome",
      "evidence": "ipt is a first-line treatment for mild to moderate major depressive episodes in adults."
    },
    {
      "head": 18,
      "tail": 24,
      "type": "has_outcome",
      "evidence": "supportive therapy is commonly used to support depressed patients."
    },
    {
      "head": 10,
      "tail": 1,
      "type": "treats",
      "evidence": "psychodynamic therapy’s efficacy in the acute phase of mdd is well-established compared to other forms of psychotherapy."
    },
    {
      "head": 25,
      "tail": 1,
      "type": "treats",
      "evidence": "supportive gt and group cbt reduce depressive symptoms."
    },
    {
      "head": 20,
      "tail": 1,
      "type": "treats",
      "evidence": "studies have shown that eight weeks of mbct treatment during remission reduces relapse."
    },
    {
      "head": 3,
      "tail": 1,
      "type": "treats",
      "evidence": "ect is the most well-known treatment for resistant depression, and solid evidence supports its effectiveness and safety."
    },
    {
      "head": 26,
      "tail": 1,
      "type": "treats",
      "evidence": "recent literature shows a significant difference between rtms and fictitious stimulation regarding its improvements in depressive symptoms."
    },
    {
      "head": 27,
      "tail": 1,
      "type": "treats",
      "evidence": "the tdcs technique significantly outperforms the simulator in terms of the rate of response and remission."
    },
    {
      "head": 4,
      "tail": 12,
      "type": "measured_by",
      "evidence": "the antidepressant effects of tdcs may involve long-term neuroplastic changes that continue to occur even after the acute phase of treatment."
    },
    {
      "head": 11,
      "tail": 12,
      "type": "measured_by",
      "evidence": "preliminary research has revealed synergistic interactions between neuro-modulation and pharmacotherapy."
    },
    {
      "head": 24,
      "tail": 12,
      "type": "measured_by",
      "evidence": "studies have shown that eight weeks of mbct treatment during remission reduces relapse."
    },
    {
      "head": 31,
      "tail": 4,
      "type": "affects",
      "evidence": "supportive gt and group cbt reduce depressive symptoms, especially in patients with common comorbid conditions."
    },
    {
      "head": 32,
      "tail": 4,
      "type": "affects",
      "evidence": "mbct is a potential alternative to reduce, or even stop, antidepressant treatment without increasing the risk of depressive recurrence, especially for patients at a high risk of relapse."
    },
    {
      "head": 33,
      "tail": 4,
      "type": "affects",
      "evidence": "ect is typically recommended for patients with severe and psychotic depression."
    },
    {
      "head": 34,
      "tail": 4,
      "type": "affects",
      "evidence": "tdcs can be used as a complementary intervention or as monotherapy to reduce depressive symptoms in unipolar or bipolar depression patients."
    },
    {
      "head": 28,
      "tail": 35,
      "type": "treats",
      "evidence": "vns is a therapeutic method that has been used for the last sixteen years to treat resistant unilateral or bipolar depression."
    },
    {
      "head": 29,
      "tail": 35,
      "type": "treats",
      "evidence": "according to the literature, dbs of the subgenual cingulate white matter elicited a clinical response in 60% of resistant depression patients."
    },
    {
      "head": 30,
      "tail": 35,
      "type": "treats",
      "evidence": "evidence supporting its effectiveness on depressive symptoms continues to grow."
    },
    {
      "head": 3,
      "tail": 35,
      "type": "treats",
      "evidence": "ect remains the most documented and effective method in this category."
    },
    {
      "head": 36,
      "tail": 1,
      "type": "treats",
      "evidence": "this treatment method is effective both for those with seasonal and non-seasonal depression."
    },
    {
      "head": 28,
      "tail": 4,
      "type": "has_outcome",
      "evidence": "vns has demonstrated progressively increasing improvements in depressive symptoms."
    },
    {
      "head": 29,
      "tail": 4,
      "type": "has_outcome",
      "evidence": "dbs elicited a clinical response in 60% of resistant depression patients after six months."
    },
    {
      "head": 30,
      "tail": 4,
      "type": "has_outcome",
      "evidence": "evidence supporting its effectiveness on depressive symptoms continues to grow."
    },
    {
      "head": 3,
      "tail": 4,
      "type": "has_outcome",
      "evidence": "ect remains the most documented and effective method in this category."
    },
    {
      "head": 36,
      "tail": 4,
      "type": "has_outcome",
      "evidence": "this treatment method is effective both for those with seasonal and non-seasonal depression."
    },
    {
      "head": 37,
      "tail": 1,
      "type": "treats",
      "evidence": "tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial."
    },
    {
      "head": 38,
      "tail": 1,
      "type": "treats",
      "evidence": "tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial."
    },
    {
      "head": 39,
      "tail": 1,
      "type": "treats",
      "evidence": "phenelzine treatment of melancholia."
    },
    {
      "head": 10,
      "tail": 1,
      "type": "treats",
      "evidence": "comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder."
    },
    {
      "head": 40,
      "tail": 11,
      "type": "affects",
      "evidence": "efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care."
    },
    {
      "head": 11,
      "tail": 12,
      "type": "measured_by",
      "evidence": "evidence-based guidelines for treating depressive disorders with antidepressants."
    },
    {
      "head": 41,
      "tail": 37,
      "type": "compares",
      "evidence": "tranylcypromine vs venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a star*d report."
    },
    {
      "head": 42,
      "tail": 1,
      "type": "treats",
      "evidence": "the effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression."
    },
    {
      "head": 43,
      "tail": 1,
      "type": "treats",
      "evidence": "efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety."
    },
    {
      "head": 44,
      "tail": 1,
      "type": "treats",
      "evidence": "allowing for non-adherence to treatment in a randomized controlled trial of two antidepressants."
    },
    {
      "head": 45,
      "tail": 1,
      "type": "treats",
      "evidence": "a comparison of venlafaxine, trazodone, and placebo in major depression."
    },
    {
      "head": 46,
      "tail": 1,
      "type": "treats",
      "evidence": "vortioxetine: a novel antidepressant for the treatment of major depressive disorder."
    },
    {
      "head": 47,
      "tail": 4,
      "type": "affects",
      "evidence": "efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety."
    },
    {
      "head": 41,
      "tail": 42,
      "type": "compares",
      "evidence": "a meta-analysis of clinical trials comparing the serotonin-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder."
    },
    {
      "head": 48,
      "tail": 41,
      "type": "measured_by",
      "evidence": "a meta-analysis of clinical trials comparing the serotonin-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder."
    },
    {
      "head": 15,
      "tail": 1,
      "type": "treats",
      "evidence": "efficacy and safety of intranasal esketamine for the treatment of major depressive disorder."
    },
    {
      "head": 49,
      "tail": 4,
      "type": "affects",
      "evidence": "riluzole combination therapy for moderate-to-severe major depressive disorder."
    },
    {
      "head": 49,
      "tail": 24,
      "type": "affects",
      "evidence": "riluzole combination therapy for moderate-to-severe major depressive disorder."
    },
    {
      "head": 50,
      "tail": 1,
      "type": "compares",
      "evidence": "riluzole combination therapy for moderate-to-severe major depressive disorder: a randomized, double-blind, placebo-controlled trial."
    },
    {
      "head": 4,
      "tail": 12,
      "type": "measured_by",
      "evidence": "riluzole combination therapy for moderate-to-severe major depressive disorder: a randomized, double-blind, placebo-controlled trial."
    },
    {
      "head": 22,
      "tail": 1,
      "type": "treats",
      "evidence": "effectiveness of problem-solving therapy for older, primary care patients with depression."
    },
    {
      "head": 16,
      "tail": 1,
      "type": "treats",
      "evidence": "professional and paraprofessional group treatments for depression: a comparison of cognitive-behavioral and mutual support interventions."
    },
    {
      "head": 52,
      "tail": 1,
      "type": "treats",
      "evidence": "interpersonal psychotherapy adapted for the group setting in the treatment of postpartum depression."
    },
    {
      "head": 53,
      "tail": 1,
      "type": "treats",
      "evidence": "portuguese and brazilian guidelines for the treatment of depression: exercise as medicine."
    },
    {
      "head": 1,
      "tail": 4,
      "type": "has_outcome",
      "evidence": "factors associated with 1-year outcome of major depression in the community."
    },
    {
      "head": 1,
      "tail": 11,
      "type": "has_outcome",
      "evidence": "health-related quality of life in a clinical trial of ect followed by continuation pharmacotherapy: effects immediately after ect and at 24 weeks."
    },
    {
      "head": 4,
      "tail": 12,
      "type": "measured_by",
      "evidence": "mindfulness-based cognitive therapy for patients with chronic, treatment-resistant depression."
    },
    {
      "head": 49,
      "tail": 1,
      "type": "affects",
      "evidence": "improvement after two sessions of electroconvulsive therapy predicts final remission in in-patients with major depression."
    },
    {
      "head": 41,
      "tail": 22,
      "type": "compares",
      "evidence": "problem-solving therapy vs supportive therapy in geriatric major depression with executive dysfunction."
    },
    {
      "head": 3,
      "tail": 54,
      "type": "treats",
      "evidence": "evidence for increased genetic risk load for major depression in patients assigned to electroconvulsive therapy."
    },
    {
      "head": 26,
      "tail": 54,
      "type": "treats",
      "evidence": "meta-analysis of the efficacy and safety of repetitive transcranial magnetic stimulation in the treatment of depression."
    },
    {
      "head": 28,
      "tail": 54,
      "type": "treats",
      "evidence": "therapeutic modalities for treatment resistant depression: focus on vagal nerve stimulation."
    },
    {
      "head": 49,
      "tail": 4,
      "type": "affects",
      "evidence": "effectiveness and safety of vagus nerve stimulation for severe treatment-resistant major depression in clinical practice after fda approval."
    },
    {
      "head": 4,
      "tail": 12,
      "type": "measured_by",
      "evidence": "volume increase in the dentate gyrus after electroconvulsive therapy in depressed patients as measured with 7t."
    },
    {
      "head": 28,
      "tail": 1,
      "type": "treats",
      "evidence": "vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial."
    },
    {
      "head": 29,
      "tail": 1,
      "type": "treats",
      "evidence": "deep brain stimulation for treatment-resistant depression."
    },
    {
      "head": 30,
      "tail": 1,
      "type": "treats",
      "evidence": "magnetic seizure therapy improves mood in refractory major depression."
    },
    {
      "head": 49,
      "tail": 4,
      "type": "affects",
      "evidence": "vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial."
    },
    {
      "head": 4,
      "tail": 12,
      "type": "measured_by",
      "evidence": "magnetic seizure therapy improves mood in refractory major depression."
    },
    {
      "head": 44,
      "tail": 1,
      "type": "treats",
      "evidence": "a total of 2,876 adult outpatients with major depressive disorder, enrolled from 18 primary and 23 psychiatric care sites, received citalopram in level 1 of star*d."
    },
    {
      "head": 43,
      "tail": 47,
      "type": "treats",
      "evidence": "in level 2, a total of 1,292 patients who did not remit with or tolerate citalopram were randomly assigned either to switch to bupropion."
    },
    {
      "head": 56,
      "tail": 47,
      "type": "treats",
      "evidence": "in level 2, patients were randomly assigned either to switch to sertraline."
    },
    {
      "head": 42,
      "tail": 47,
      "type": "treats",
      "evidence": "in level 2, patients were randomly assigned either to switch to venlafaxine."
    },
    {
      "head": 57,
      "tail": 47,
      "type": "treats",
      "evidence": "patients were designated as having anxious depression if their anxiety/somatization factor score from the 17-item hamilton depression was 7 or higher at baseline."
    },
    {
      "head": 47,
      "tail": 4,
      "type": "has_outcome",
      "evidence": "anxious depression is associated with poorer acute outcomes than nonanxious depression following antidepressant treatment."
    },
    {
      "head": 47,
      "tail": 58,
      "type": "has_outcome",
      "evidence": "rates of remission and response as well as times to remission and response were compared between patients with anxious depression and those with nonanxious depression."
    },
    {
      "head": 59,
      "tail": 47,
      "type": "compares",
      "evidence": "the authors conducted a secondary data analysis to compare antidepressant treatment outcomes for patients with anxious and nonanxious major depression in levels 1 and 2 of the star*d study."
    },
    {
      "head": 4,
      "tail": 12,
      "type": "measured_by",
      "evidence": "patients were designated as having anxious depression if their anxiety/somatization factor score from the 17-item hamilton depression was 7 or higher at baseline."
    },
    {
      "head": 58,
      "tail": 12,
      "type": "measured_by",
      "evidence": "ratings of side effect frequency, intensity, and burden, as well as the number of serious adverse events, were significantly greater in the anxious depression group."
    },
    {
      "head": 44,
      "tail": 1,
      "type": "treats",
      "evidence": "the aim of citalopram treatment in level 1 was to achieve symptom remission."
    },
    {
      "head": 44,
      "tail": 4,
      "type": "has_outcome",
      "evidence": "the aim of citalopram treatment in level 1 was to achieve symptom remission, which was defined as qids-c score ≤5."
    },
    {
      "head": 44,
      "tail": 11,
      "type": "has_outcome",
      "evidence": "response was defined as a reduction of ≥50% from baseline in the qids score at the last assessment."
    },
    {
      "head": 4,
      "tail": 12,
      "type": "measured_by",
      "evidence": "logistic regression models were used to compare remission and response rates after adjustment for baseline severity of depression."
    },
    {
      "head": 60,
      "tail": 1,
      "type": "measured_by",
      "evidence": "patients completed the version of the qids."
    },
    {
      "head": 44,
      "tail": 1,
      "type": "treats",
      "evidence": "patients with anxious depression made fewer visits and spent less time in treatment than those without anxious depression."
    },
    {
      "head": 44,
      "tail": 4,
      "type": "has_outcome",
      "evidence": "remission was defined as an exit ham-d score ≤7 or last observed qids score ≤5."
    },
    {
      "head": 44,
      "tail": 11,
      "type": "has_outcome",
      "evidence": "response was defined as a reduction of ≥50% from baseline in the qids score at the last assessment."
    },
    {
      "head": 41,
      "tail": 37,
      "type": "compares",
      "evidence": "tranylcypromine vs venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a star*d report."
    },
    {
      "head": 4,
      "tail": 12,
      "type": "measured_by",
      "evidence": "patients were designated as having anxious depression if their anxiety/somatization factor score from the 17-item hamilton depression was 7 or higher at baseline."
    },
    {
      "head": 41,
      "tail": 22,
      "type": "compares",
      "evidence": "problem-solving therapy vs supportive therapy in geriatric major depression with executive dysfunction."
    },
    {
      "head": 3,
      "tail": 54,
      "type": "treats",
      "evidence": "evidence for increased genetic risk load for major depression in patients assigned to electroconvulsive therapy."
    },
    {
      "head": 26,
      "tail": 54,
      "type": "treats",
      "evidence": "meta-analysis of the efficacy and safety of repetitive transcranial magnetic stimulation in the treatment of depression."
    },
    {
      "head": 28,
      "tail": 54,
      "type": "treats",
      "evidence": "therapeutic modalities for treatment resistant depression: focus on vagal nerve stimulation."
    },
    {
      "head": 49,
      "tail": 4,
      "type": "affects",
      "evidence": "effectiveness and safety of vagus nerve stimulation for severe treatment-resistant major depression in clinical practice after fda approval."
    },
    {
      "head": 4,
      "tail": 12,
      "type": "measured_by",
      "evidence": "volume increase in the dentate gyrus after electroconvulsive therapy in depressed patients as measured with 7t."
    },
    {
      "head": 28,
      "tail": 1,
      "type": "treats",
      "evidence": "vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial."
    },
    {
      "head": 29,
      "tail": 1,
      "type": "treats",
      "evidence": "deep brain stimulation for treatment-resistant depression."
    },
    {
      "head": 30,
      "tail": 1,
      "type": "treats",
      "evidence": "magnetic seizure therapy improves mood in refractory major depression."
    },
    {
      "head": 49,
      "tail": 4,
      "type": "affects",
      "evidence": "vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial."
    },
    {
      "head": 4,
      "tail": 12,
      "type": "measured_by",
      "evidence": "magnetic seizure therapy improves mood in refractory major depression."
    },
    {
      "head": 44,
      "tail": 1,
      "type": "treats",
      "evidence": "a total of 2,876 adult outpatients with major depressive disorder, enrolled from 18 primary and 23 psychiatric care sites, received citalopram in level 1 of star*d."
    },
    {
      "head": 43,
      "tail": 47,
      "type": "treats",
      "evidence": "in level 2, a total of 1,292 patients who did not remit with or tolerate citalopram were randomly assigned either to switch to bupropion."
    },
    {
      "head": 56,
      "tail": 47,
      "type": "treats",
      "evidence": "in level 2, patients were randomly assigned either to switch to sertraline."
    },
    {
      "head": 42,
      "tail": 47,
      "type": "treats",
      "evidence": "in level 2, patients were randomly assigned either to switch to venlafaxine."
    },
    {
      "head": 47,
      "tail": 4,
      "type": "has_outcome",
      "evidence": "remission rates were significantly lower in patients with anxious depression..."
    },
    {
      "head": 47,
      "tail": 11,
      "type": "has_outcome",
      "evidence": "response rates were also significantly lower for patients with anxious depression..."
    },
    {
      "head": 61,
      "tail": 4,
      "type": "affects",
      "evidence": "patients could discontinue citalopram before 12 weeks if intolerable side effects made a medication change necessary."
    },
    {
      "head": 59,
      "tail": 44,
      "type": "compares",
      "evidence": "patients whose symptoms responded or remitted could enter the 12-month naturalistic follow-up phase, but all who did not achieve remission were encouraged to enter the next randomized trial in the star*d sequence."
    },
    {
      "head": 4,
      "tail": 12,
      "type": "measured_by",
      "evidence": "the primary outcome measure was the ham-d score, obtained by research outcome assessors using telephone-based structured interviews."
    },
    {
      "head": 60,
      "tail": 1,
      "type": "measured_by",
      "evidence": "patients completed the version of the qids."
    },
    {
      "head": 44,
      "tail": 1,
      "type": "treats",
      "evidence": "patients with anxious depression made fewer visits and spent less time in treatment than those without anxious depression."
    },
    {
      "head": 44,
      "tail": 4,
      "type": "has_outcome",
      "evidence": "remission was defined as an exit ham-d score ≤7 or last observed qids score ≤5."
    },
    {
      "head": 44,
      "tail": 11,
      "type": "has_outcome",
      "evidence": "response was defined as a reduction of ≥50% from baseline in the qids score at the last assessment."
    },
    {
      "head": 41,
      "tail": 37,
      "type": "compares",
      "evidence": "tranylcypromine vs venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a star*d report."
    },
    {
      "head": 59,
      "tail": 48,
      "type": "compares",
      "evidence": "medication augmentation after the failure of ssris for depression."
    }
  ],
  "interactions": [
    {
      "entity_1": "selective serotonin reuptake inhibitors",
      "entity_2": "monoamine oxidase inhibitors",
      "type": "contraindication",
      "source": "clinical guidelines/FDA labeling (risk of serotonin syndrome; requires washout period)"
    },
    {
      "entity_1": "monoamine oxidase inhibitors",
      "entity_2": "tricyclic antidepressants",
      "type": "contraindication",
      "source": "clinical guidelines (risk of hypertensive crisis and severe adverse effects)"
    },
    {
      "entity_1": "tranylcypromine",
      "entity_2": "venlafaxine",
      "type": "contraindication",
      "source": "clinical guidelines (MAOI combined with SNRI poses high risk of serotonin syndrome/hypertensive events)"
    },
    {
      "entity_1": "monoamine oxidase inhibitors",
      "entity_2": "bupropion",
      "type": "contraindication",
      "source": "clinical guidelines (concomitant use can cause hypertensive reactions and other severe adverse events)"
    },
    {
      "entity_1": "fluoxetine",
      "entity_2": "imipramine",
      "type": "conflict",
      "source": "clinical pharmacology (fluoxetine inhibits CYP2D6, can increase TCA levels and toxicity)"
    },
    {
      "entity_1": "fluoxetine",
      "entity_2": "nortriptyline",
      "type": "conflict",
      "source": "clinical pharmacology (CYP interactions increasing TCA concentrations)"
    },
    {
      "entity_1": "tricyclic antidepressants",
      "entity_2": "selective serotonin reuptake inhibitors",
      "type": "conflict",
      "source": "clinical guidelines/clinical pharmacology (risk of pharmacokinetic interactions and serotonin syndrome)"
    },
    {
      "entity_1": "trazodone",
      "entity_2": "monoamine oxidase inhibitors",
      "type": "contraindication",
      "source": "clinical guidelines (risk of serotonin syndrome)"
    },
    {
      "entity_1": "benzodiazepine",
      "entity_2": "electroconvulsive therapy",
      "type": "conflict",
      "source": "clinical guidance (benzodiazepines can raise seizure threshold and may reduce ECT efficacy)"
    },
    {
      "entity_1": "benzodiazepine",
      "entity_2": "ketamine",
      "type": "conflict",
      "source": "clinical studies (benzodiazepines may attenuate ketamine's antidepressant effect and increase sedation)"
    },
    {
      "entity_1": "benzodiazepine",
      "entity_2": "esketamine",
      "type": "conflict",
      "source": "FDA labeling and clinical guidance (concomitant CNS depressants increase sedation; monitor closely)"
    },
    {
      "entity_1": "trazodone",
      "entity_2": "benzodiazepine",
      "type": "conflict",
      "source": "drug labeling/clinical guidance (additive sedation and respiratory depression risk)"
    },
    {
      "entity_1": "esketamine",
      "entity_2": "monoamine oxidase inhibitors",
      "type": "conflict",
      "source": "FDA labeling/clinical guidance (caution/avoid due to potential for exaggerated sympathetic effects and limited safety data)"
    },
    {
      "entity_1": "repetitive transcranial magnetic stimulation",
      "entity_2": "selective serotonin reuptake inhibitors",
      "type": "synergy",
      "source": "preliminary research (relationships: synergistic interactions between neuromodulation and pharmacotherapy)"
    },
    {
      "entity_1": "transcranial direct current stimulation",
      "entity_2": "antidepressant therapy",
      "type": "synergy",
      "source": "preliminary research (relationships indicate potential synergistic effects with pharmacotherapy)"
    },
    {
      "entity_1": "electroconvulsive therapy",
      "entity_2": "antidepressant therapy",
      "type": "synergy",
      "source": "relationships in provided data (combining somatic therapies and pharmacotherapy for resistant depression)"
    },
    {
      "entity_1": "cognitive behavioral therapy",
      "entity_2": "selective serotonin reuptake inhibitors",
      "type": "synergy",
      "source": "relationships in provided data (combination of medications and psychotherapy often more effective)"
    },
    {
      "entity_1": "mindfulness-based cognitive therapy",
      "entity_2": "antidepressant therapy",
      "type": "synergy",
      "source": "relationships in provided data (mbct may allow reduction/discontinuation of antidepressants in some patients)"
    },
    {
      "entity_1": "bupropion",
      "entity_2": "electroconvulsive therapy",
      "type": "conflict",
      "source": "clinical pharmacology/ECT guidance (bupropion lowers seizure threshold; caution regarding seizure control and potential prolonged seizures)"
    },
    {
      "entity_1": "vortioxetine",
      "entity_2": "selective serotonin reuptake inhibitors",
      "type": "conflict",
      "source": "clinical pharmacology (concurrent serotonergic agents increase risk of serotonin syndrome)"
    },
    {
      "entity_1": "benzodiazepine",
      "entity_2": "cognitive behavioral therapy",
      "type": "conflict",
      "source": "psychotherapy literature (benzodiazepines may impair exposure-based learning and reduce effectiveness of some CBT components) "
    }
  ]
}